Browsing by Subject "Adjuvant Tamoxifen"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    The ethics of CYP2D6 testing for patients considering tamoxifen
    (BioMed Central, 2007-04-13) Hartman, Anne-Renee; Helft, Paul; Medicine, School of Medicine
    The CYP2D6 gene is responsible for the majority of tamoxifen metabolism. Recent compelling, yet limited data have determined that postmenopausal women who carry a functional polymorphism in the CYP2D6 gene have a worse clinical outcome than women who have a wild-type genotype. In this commentary we discuss the level of evidence needed to change clinical practice and whether CYP2D6 genotyping is appropriate for all women considering tamoxifen as part of their adjuvant therapy.